Poor
Misaligned
Patient Risk:
Medium
Summary
Many statements are either not supported by the provided ALDACTONE (spironolactone) label excerpts (notably acne/hirsutism and several dermatologic/endocrine indications, and multiple dosing/monitoring specifics) or are potentially inaccurate relative to the label excerpts (e.g., “blocks androgen receptors” as a label-supported reason, hypertension/heart-failure efficacy wording beyond excerpts, and initiation/max dose claims not fully consistent with provided dosing ranges).
Category Scores
Accurate Statements
Amneal Pharmaceuticals produces a generic version of spironolactone.
Not directly supported by provided label excerpts (label excerpts do not mention Amneal/generic manufacture).
Spironolactone is a potassium-sparing diuretic.
Supported indirectly by label mechanism/pharmacodynamics: spironolactone increases sodium/water excretion while potassium is retained (12.1).
Spironolactone is the active ingredient of Amneal and other spironolactone products.
Supported by label description: ALDACTONE tablets contain spironolactone (11). Generic active ingredient alignment is implied but not explicitly stated in excerpts.
Amneal spironolactone is available in 25 mg and 50 mg tablets.
Supported by label strengths: 25 mg and 50 mg tablets are listed (11 and 16). Amneal-specific labeling not shown, but strengths for spironolactone tablets are consistent.
For hypertension, spironolactone lowers blood pressure.
Supported: ALDACTONE indicated as add-on therapy for hypertension to lower blood pressure (1).
For heart failure, spironolactone reduces edema.
Supported: indicated to manage edema in NYHA Class III–IV heart failure (1).
For hyperaldosteronism, spironolactone counters excess aldosterone.
Supported in concept by indication for primary hyperaldosteronism (1) and mechanism as aldosterone antagonist (12.1).
Typical starting dose for hypertension or heart failure is 25 mg once daily.
Partially supported for heart failure: initiate at 25 mg once daily in patients with serum potassium ≤5.0 and eGFR >50 (2.2). Hypertension initial dose is “25 to 100 mg” (2.3), so “typical starting dose 25 mg once daily” is not fully supported.
The maximum recommended dose of spironolactone is 200 mg daily.
Partially supported: edema dosing may range from 25 to 200 mg daily (2.4). Not supported as universal “maximum recommended dose” across all indications.
Hyperkalemia is the most serious risk of spironolactone.
Supported by label emphasis: hyperkalemia described in contraindications and major warnings (4, 5.1).
Gynecomastia and breast tenderness are side effects.
Supported: gynecomastia is a known adverse reaction/precaution (5.4 and 6).
Electrolyte disturbances are a common side effect category of spironolactone.
Supported generally: electrolyte/metabolic abnormalities are described in warnings and adverse reactions (5.3, 6).
Spironolactone should be titrated gradually while monitoring blood pressure, electrolytes, and renal function.
Supported in part: monitor volume status and renal function periodically (5.2) and monitor electrolytes (5.3). The excerpt does not explicitly say “blood pressure” for titration, but blood pressure monitoring is consistent with use; monitoring language is incomplete in excerpts.
Serum potassium should be checked 1–2 weeks after starting therapy.
Partially supported: label states monitor serum potassium within 1 week of initiation or titration (5.1). The “1–2 weeks” framing is broader than label.
Concomitant use of spironolactone with ACE inhibitors can amplify hyperkalemia risk.
Supported via listing of ACE inhibitors as drugs that can increase potassium and risk of severe hyperkalemia (7.1).
Concomitant use of spironolactone with ARBs can amplify hyperkalemia risk.
Supported via listing of ACE inhibitors/ARBs category as increasing potassium (7.1).
Concomitant use of spironolactone with potassium supplements can amplify hyperkalemia risk.
Supported: potassium supplementation can lead to severe hyperkalemia (7.1) and patient counseling to avoid potassium supplements (17).
Spironolactone is a small molecule drug.
Not explicitly stated in excerpts; mechanism/chemical description implies non-biologic. Excerpt does not explicitly mention “small molecule.”
Spironolactone’s core patents in the U.S. expired many years ago.
Not supported by provided labeling excerpts (no patent/regulatory exclusivity content).
Spironolactone is widely available as a generic.
Not supported by provided labeling excerpts (no marketplace statements).
Store below 77°F (25°C).
Supported: storage instruction (16).
Unsupported Statements
Amneal often sells at a lower wholesale cost.
Not supported by prescribing information excerpts.
Lower wholesale cost can translate to savings on patient copays.
Not supported by prescribing information excerpts.
Most major insurers list spironolactone as a generic.
Not supported by prescribing information excerpts.
Generic tier coverage typically results in lower copays or full coverage.
Not supported by prescribing information excerpts.
Coverage for spironolactone may vary by insurance plan.
Not supported by prescribing information excerpts.
For hypertension, spironolactone lowers blood pressure especially when combined with a loop diuretic or an ACE inhibitor.
Label excerpt for hypertension indicates add-on therapy for patients not adequately controlled on other agents, but the specific “loop diuretic” and “ACE inhibitor” combination emphasis is not supported in the provided excerpts.
For heart failure, spironolactone improves cardiac output.
Not supported by the provided heart failure indication/excerpted trial information (only survival/hospitalization/edema are shown).
For dermatologic conditions, spironolactone treats acne.
Dermatologic indications (acne) are not included in provided label indications (1).
For dermatologic conditions, spironolactone treats hirsutism.
Dermatologic indications (hirsutism) are not included in provided label indications (1).
Spironolactone blocks androgen receptors.
Label excerpt for mechanism focuses on aldosterone antagonism (12.1). Androgen receptor binding is mentioned in the provided excerpt only as part of the interaction with abiraterone (7.7), but the general statement is not supported as a mechanism for labeled uses.
Spironolactone treats acne and hirsutism by blocking androgen receptors.
Not supported because acne/hirsutism indications are not in provided label excerpts (1), and the androgen-receptor mechanism is not connected to those uses in the excerpt.
For endocrine disorders, spironolactone is used in congenital adrenal hyperplasia.
Not supported by provided label indications (1).
For endocrine disorders, spironolactone is used in polycystic ovary syndrome.
Not supported by provided label indications (1).
In congenital adrenal hyperplasia and polycystic ovary syndrome, spironolactone reduces androgen-mediated symptoms.
Not supported; those conditions are not included in provided label indications.
For dermatologic uses, spironolactone dosing can go up to 100–200 mg per day.
Dermatologic uses not supported in provided label indications (1), so dermatology dosing is unsupported.
For dermatologic uses, the dosing can be split into two or three doses.
Not supported; splitting is not provided for dermatologic uses in label excerpts.
Spironolactone is approved for hypertension.
Supported conceptually (1), but the phrasing is ambiguous because the label excerpt specifies add-on therapy for hypertension with inadequate control; still largely consistent but not fully specific. Marked unsupported only if strictly interpreted as broad monotherapy approval.
Amneal packaging and price may differ from other generics.
Not supported by prescribing information excerpts.
Amneal tablets are identical in strength and dosage form to those from Teva, Mylan, and Sandoz.
Not supported by prescribing information excerpts.
Amneal packaging and price may differ from other generics.
Not supported by prescribing information excerpts.
Most major insurers list spironolactone as a generic.
Not supported by prescribing information excerpts.
Patients should monitor blood pressure with daily readings to gauge effectiveness while on spironolactone.
Not supported in provided excerpts; label excerpts mention monitoring serum potassium, electrolytes, volume status/renal function, but not “daily blood pressure readings.”
Changes in urine output may indicate fluid status while on spironolactone.
Not supported explicitly in provided excerpts.
Signs of gynecomastia or menstrual changes should be reported promptly to the prescriber.
Gynecomastia risk is mentioned (5.4), but “menstrual changes” reporting instruction is not explicitly in provided excerpts.
St. John’s Wort may lower spironolactone levels.
Not supported by provided drug interaction excerpts (7).
Rifampin may lower spironolactone levels.
Not supported by provided drug interaction excerpts (7).
Certain antiepileptics may lower spironolactone levels.
Not supported by provided drug interaction excerpts (7).
Menstrual irregularities are a side effect category.
Irregular menses/amenorrhea are listed among adverse reactions (6), so this is supported; however the “side effect category” framing is less specific. Still, label excerpt supports the existence; thus not counted as unsupported.
Gastrointestinal upset symptoms can include nausea, diarrhea, or abdominal pain.
Label excerpt includes nausea/vomiting/diarrhea/cramping/gastric bleeding/gastritis (6), but “abdominal pain” is not explicitly shown in excerpt; partially supported. Marked unsupported only if requiring exact symptom set.
Contradictions
Low
AI Statement
Spironolactone blocks androgen receptors.
Label Reference
7.7 states spironolactone binds to the androgen receptor in the context of interaction with abiraterone; however the general mechanism statement conflicts with the label’s primary mechanism focus on aldosterone antagonism (12.1) when presented as a standalone mechanism for labeled uses.
Important Omissions
Contraindications other than hyperkalemia were not listed: Addison’s disease and concomitant use of eplerenone (4).
Importance:
Moderate
Label-directed monitoring after initiation/titration: monitor serum potassium within 1 week (5.1) and adjust/dose-reduce approach for hyperkalemia (5.1) were not fully and precisely stated.
Importance:
Moderate
Food-consistency instruction: take with or without food but consistently with respect to food (2.1) was not mentioned.
Importance:
Moderate
Hypertension dosing ceiling: doses >100 mg/day generally do not provide additional BP reductions (2.3) not clearly conveyed.
Importance:
Moderate
Overlooked interaction cautions included in provided excerpts (beyond ACE/ARB/potassium): lithium monitoring (7.2), NSAID monitoring (7.3), and specific “abiraterone not recommended” and “avoid mitotane” (7.7–7.8).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Multiple statements are not supported by the provided label excerpts (notably dermatologic/acne/hirsutism and endocrine conditions), and several dosing/monitoring details are broader or not label-consistent (e.g., hypertension starting dose framing, universal “max dose,” and monitoring specificity). Omission of key contraindications (Addison’s disease and eplerenone) and omission/incompleteness of interaction cautions could contribute to unsafe misunderstanding.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Misaligned
Primary Issue
Large portion of claims (indications for acne/hirsutism and congenital adrenal hyperplasia/PCOS) are not present in the provided ALDACTONE label excerpts; multiple other claims (dose/monitoring specifics and interactions) are partially supported or not supported.
Suggested Improvement
Limit claims to the provided ALDACTONE label excerpts: use only listed indications (heart failure NYHA III–IV with reduced EF, add-on hypertension, edema in specified conditions, and primary hyperaldosteronism), use label-supported dosing ranges per indication, precisely reflect potassium monitoring timing and contraindications (hyperkalemia, Addison’s disease, eplerenone), and restrict interactions to those explicitly listed in the provided excerpts.